POC Molecular Diagnostics Market Size, Share and Growth Outlook 2026: By Product and Service, By Technology, By Application, By Test Location, Companies to 2034
The global POC Molecular Diagnostics Market size is forecast to increase from $4.47 Billion in 2026 to $7.83 Billion in 2034 at a CAGR of 7.26% between 2026 and 2034.
The POC Molecular Diagnostics market report provides detailed analysis and outlook of POC Molecular Diagnostics segments including By Product and Service (Instruments / Analyzers, Assay Kits, Reagents, and Consumables, Software and Connectivity Services), By Technology (Polymerase Chain Reaction (PCR-based), Isothermal Amplification, Hybridization and Microarray Technologies, Other Technologies ), By Application (Infectious Diseases, Respiratory Infections, Sexually Transmitted Infections, Healthcare-Associated Infections, Hepatitis and HIV, Oncology and Cancer Diagnostics, Hematology and Genetic Testing), By Test Location (Hospitals and Emergency Rooms, Physician Offices, Clinics, and Urgent Care Centers, Over-the-Counter (OTC) / Self-Testing and Homecare Settings, Research and Academic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Molecular Diagnostics Industry Overview
Decentralized Molecular Testing, Rapid PCR Technologies, and Near-Patient Diagnostics are Driving the Point-of-Care Molecular Diagnostics Industry
The Point-of-Care Molecular Diagnostics industry is experiencing rapid growth as healthcare systems increasingly prioritize decentralized testing, rapid clinical decision-making, and expanded access to laboratory-quality diagnostics outside traditional laboratory environments. Advances in miniaturized molecular platforms, cartridge-based PCR technologies, multiplex pathogen detection, and simplified sample preparation workflows are transforming how infectious diseases are diagnosed across physician offices, emergency departments, urgent care centers, pharmacies, and community healthcare settings. The industry is shifting from centralized molecular testing paradigms toward highly portable, automated diagnostic systems capable of delivering rapid and actionable results with minimal operator intervention. Regulatory support for CLIA-waived molecular testing platforms is further accelerating adoption across decentralized healthcare environments.
Rapid Molecular Platforms are Expanding Near-Patient Diagnostic Capabilities
One of the primary trends driving the point-of-care molecular diagnostics market is the development of ultra-fast molecular platforms capable of delivering laboratory-grade performance within clinically actionable timeframes. Healthcare providers increasingly require diagnostic systems that support immediate treatment decisions while maintaining analytical sensitivity and specificity. Roche's FDA-cleared and CLIA-waived Bordetella molecular assay on the cobas Liat platform demonstrates the growing role of rapid PCR technologies capable of detecting multiple pathogens directly at the point of care within minutes. Similarly, QuidelOrtho's acquisition of LEX Diagnostics and integration of the VELO molecular platform reflects the increasing strategic importance of decentralized multiplex RT-PCR technologies capable of diagnosing major respiratory pathogens without complex laboratory infrastructure. These developments highlight the industry's transition toward rapid, accessible, and highly automated molecular diagnostics.
Host-Response Diagnostics and Simplified Testing Workflows are Broadening Clinical Applications
The point-of-care diagnostics market is also expanding beyond direct pathogen detection through the integration of host-response biomarkers and simplified testing architectures designed for broad clinical deployment. Healthcare providers increasingly recognize the value of biomarker-based diagnostics that support treatment decisions, antimicrobial stewardship, and patient triage. Phase Scientific Americas' expansion of the FebriDx platform exemplifies this trend through its use of dual host-response biomarkers, including Myxovirus resistance protein A and C-reactive protein, to differentiate acute respiratory infections without requiring specialized instrumentation. The combination of instrument-free operation, rapid turnaround times, and expanding reimbursement support illustrates the broader market movement toward accessible, decentralized diagnostic solutions that improve clinical decision-making while reducing dependence on centralized laboratory infrastructure.
POC Molecular Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global POC Molecular Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Cepheid (Danaher Corporation), Roche Diagnostics, bioM?rieux SA, QuidelOrtho Corporation, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., Becton, Dickinson and Company, Meridian Bioscience. The POC Molecular Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the POC Molecular Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in POC Molecular Diagnostics industry include- Abbott Laboratories, Cepheid (Danaher Corporation), Roche Diagnostics, bioM?rieux SA, QuidelOrtho Corporation, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., Becton, Dickinson and Company, Meridian Bioscience. The POC Molecular Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US POC Molecular Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the POC Molecular Diagnostics market remains one of the strongest-performing segments in the country.
The US POC Molecular Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US POC Molecular Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across POC Molecular Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian POC Molecular Diagnostics markets
Canada's strong POC Molecular Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian POC Molecular Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany POC Molecular Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest POC Molecular Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of POC Molecular Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany POC Molecular Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the POC Molecular Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support POC Molecular Diagnostics sales through 2034
France POC Molecular Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK POC Molecular Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of POC Molecular Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China POC Molecular Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China POC Molecular Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of POC Molecular Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese POC Molecular Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India POC Molecular Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian POC Molecular Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil POC Molecular Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa POC Molecular Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
POC Molecular Diagnostics Market Segmentation
By Product and Service
Instruments / Analyzers
Assay Kits, Reagents, and Consumables
Software and Connectivity Services
By Technology
Polymerase Chain Reaction (PCR-based)
Isothermal Amplification
Hybridization and Microarray Technologies
Other Technologies
By Application
Infectious Diseases
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Associated Infections
Hepatitis and HIV
Oncology and Cancer Diagnostics
Hematology and Genetic Testing
By Test Location
Hospitals and Emergency Rooms
Physician Offices, Clinics, and Urgent Care Centers
Over-the-Counter (OTC) / Self-Testing and Homecare Settings
Research and Academic Laboratories
Leading Companies in POC Molecular Diagnostics Industry (2026)
Abbott Laboratories
Cepheid (Danaher Corporation)
Roche Diagnostics
bioM?rieux SA
QuidelOrtho Corporation
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
Becton, Dickinson and Company
Meridian Bioscience
Countries Included
The POC Molecular Diagnostics market report provides detailed analysis and outlook of POC Molecular Diagnostics segments including By Product and Service (Instruments / Analyzers, Assay Kits, Reagents, and Consumables, Software and Connectivity Services), By Technology (Polymerase Chain Reaction (PCR-based), Isothermal Amplification, Hybridization and Microarray Technologies, Other Technologies ), By Application (Infectious Diseases, Respiratory Infections, Sexually Transmitted Infections, Healthcare-Associated Infections, Hepatitis and HIV, Oncology and Cancer Diagnostics, Hematology and Genetic Testing), By Test Location (Hospitals and Emergency Rooms, Physician Offices, Clinics, and Urgent Care Centers, Over-the-Counter (OTC) / Self-Testing and Homecare Settings, Research and Academic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Point-of-Care Molecular Diagnostics Industry Overview
Decentralized Molecular Testing, Rapid PCR Technologies, and Near-Patient Diagnostics are Driving the Point-of-Care Molecular Diagnostics Industry
The Point-of-Care Molecular Diagnostics industry is experiencing rapid growth as healthcare systems increasingly prioritize decentralized testing, rapid clinical decision-making, and expanded access to laboratory-quality diagnostics outside traditional laboratory environments. Advances in miniaturized molecular platforms, cartridge-based PCR technologies, multiplex pathogen detection, and simplified sample preparation workflows are transforming how infectious diseases are diagnosed across physician offices, emergency departments, urgent care centers, pharmacies, and community healthcare settings. The industry is shifting from centralized molecular testing paradigms toward highly portable, automated diagnostic systems capable of delivering rapid and actionable results with minimal operator intervention. Regulatory support for CLIA-waived molecular testing platforms is further accelerating adoption across decentralized healthcare environments.
Rapid Molecular Platforms are Expanding Near-Patient Diagnostic Capabilities
One of the primary trends driving the point-of-care molecular diagnostics market is the development of ultra-fast molecular platforms capable of delivering laboratory-grade performance within clinically actionable timeframes. Healthcare providers increasingly require diagnostic systems that support immediate treatment decisions while maintaining analytical sensitivity and specificity. Roche's FDA-cleared and CLIA-waived Bordetella molecular assay on the cobas Liat platform demonstrates the growing role of rapid PCR technologies capable of detecting multiple pathogens directly at the point of care within minutes. Similarly, QuidelOrtho's acquisition of LEX Diagnostics and integration of the VELO molecular platform reflects the increasing strategic importance of decentralized multiplex RT-PCR technologies capable of diagnosing major respiratory pathogens without complex laboratory infrastructure. These developments highlight the industry's transition toward rapid, accessible, and highly automated molecular diagnostics.
Host-Response Diagnostics and Simplified Testing Workflows are Broadening Clinical Applications
The point-of-care diagnostics market is also expanding beyond direct pathogen detection through the integration of host-response biomarkers and simplified testing architectures designed for broad clinical deployment. Healthcare providers increasingly recognize the value of biomarker-based diagnostics that support treatment decisions, antimicrobial stewardship, and patient triage. Phase Scientific Americas' expansion of the FebriDx platform exemplifies this trend through its use of dual host-response biomarkers, including Myxovirus resistance protein A and C-reactive protein, to differentiate acute respiratory infections without requiring specialized instrumentation. The combination of instrument-free operation, rapid turnaround times, and expanding reimbursement support illustrates the broader market movement toward accessible, decentralized diagnostic solutions that improve clinical decision-making while reducing dependence on centralized laboratory infrastructure.
POC Molecular Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global POC Molecular Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Cepheid (Danaher Corporation), Roche Diagnostics, bioM?rieux SA, QuidelOrtho Corporation, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., Becton, Dickinson and Company, Meridian Bioscience. The POC Molecular Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the POC Molecular Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth POC Molecular Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by POC Molecular Diagnostics companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional POC Molecular Diagnostics markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in POC Molecular Diagnostics industry include- Abbott Laboratories, Cepheid (Danaher Corporation), Roche Diagnostics, bioM?rieux SA, QuidelOrtho Corporation, Hologic, Inc., Thermo Fisher Scientific, QIAGEN N.V., Becton, Dickinson and Company, Meridian Bioscience. The POC Molecular Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US POC Molecular Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the POC Molecular Diagnostics market remains one of the strongest-performing segments in the country.
The US POC Molecular Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US POC Molecular Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across POC Molecular Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian POC Molecular Diagnostics markets
Canada's strong POC Molecular Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian POC Molecular Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany POC Molecular Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest POC Molecular Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of POC Molecular Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany POC Molecular Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the POC Molecular Diagnostics market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support POC Molecular Diagnostics sales through 2034
France POC Molecular Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK POC Molecular Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of POC Molecular Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China POC Molecular Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China POC Molecular Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of POC Molecular Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese POC Molecular Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India POC Molecular Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian POC Molecular Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil POC Molecular Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa POC Molecular Diagnostics Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
POC Molecular Diagnostics Market Segmentation
By Product and Service
Instruments / Analyzers
Assay Kits, Reagents, and Consumables
Software and Connectivity Services
By Technology
Polymerase Chain Reaction (PCR-based)
Isothermal Amplification
Hybridization and Microarray Technologies
Other Technologies
By Application
Infectious Diseases
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Associated Infections
Hepatitis and HIV
Oncology and Cancer Diagnostics
Hematology and Genetic Testing
By Test Location
Hospitals and Emergency Rooms
Physician Offices, Clinics, and Urgent Care Centers
Over-the-Counter (OTC) / Self-Testing and Homecare Settings
Research and Academic Laboratories
Leading Companies in POC Molecular Diagnostics Industry (2026)
Abbott Laboratories
Cepheid (Danaher Corporation)
Roche Diagnostics
bioM?rieux SA
QuidelOrtho Corporation
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
Becton, Dickinson and Company
Meridian Bioscience
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential POC Molecular Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the POC Molecular Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POC MOLECULAR DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global POC Molecular Diagnostics Markets in 2026
3.2. Global Historic and Forecast POC Molecular Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key POC Molecular Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential POC Molecular Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across POC Molecular Diagnostics Value Chain
CHAPTER 4- POC MOLECULAR DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading POC Molecular Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POC MOLECULAR DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service
Instruments / Analyzers
Assay Kits, Reagents, and Consumables
Software and Connectivity Services
By Technology
Polymerase Chain Reaction (PCR-based)
Isothermal Amplification
Hybridization and Microarray Technologies
Other Technologies
By Application
Infectious Diseases
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Associated Infections
Hepatitis and HIV
Oncology and Cancer Diagnostics
Hematology and Genetic Testing
By Test Location
Hospitals and Emergency Rooms
Physician Offices, Clinics, and Urgent Care Centers
Over-the-Counter (OTC) / Self-Testing and Homecare Settings
Research and Academic Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America POC Molecular Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America POC Molecular Diagnostics Market Size Outlook by Type
7.6. North America POC Molecular Diagnostics Market Size Outlook by Application
7.7. North America POC Molecular Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US POC Molecular Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada POC Molecular Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico POC Molecular Diagnostics Companies
CHAPTER 8- EUROPE POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe POC Molecular Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe POC Molecular Diagnostics Market Size Outlook by Type
8.6. Europe POC Molecular Diagnostics Market Size Outlook by Application
8.7. Europe POC Molecular Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany POC Molecular Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France POC Molecular Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK POC Molecular Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain POC Molecular Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy POC Molecular Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe POC Molecular Diagnostics Companies
CHAPTER 9- ASIA PACIFIC POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific POC Molecular Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Type
9.6. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Application
9.7. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China POC Molecular Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan POC Molecular Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India POC Molecular Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea POC Molecular Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia POC Molecular Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia POC Molecular Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America POC Molecular Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America POC Molecular Diagnostics Market Size Outlook by Type
10.6. South and Central America POC Molecular Diagnostics Market Size Outlook by Application
10.7. South and Central America POC Molecular Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil POC Molecular Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina POC Molecular Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America POC Molecular Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa POC Molecular Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia POC Molecular Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE POC Molecular Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa POC Molecular Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in POC Molecular Diagnostics Industry
Abbott Laboratories
Cepheid (Danaher Corporation)
Roche Diagnostics
bioM?rieux SA
QuidelOrtho Corporation
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
Becton, Dickinson and Company
Meridian Bioscience
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential POC Molecular Diagnostics Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the POC Molecular Diagnostics Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL POC MOLECULAR DIAGNOSTICS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global POC Molecular Diagnostics Markets in 2026
3.2. Global Historic and Forecast POC Molecular Diagnostics Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key POC Molecular Diagnostics Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential POC Molecular Diagnostics Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across POC Molecular Diagnostics Value Chain
CHAPTER 4- POC MOLECULAR DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading POC Molecular Diagnostics Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- POC MOLECULAR DIAGNOSTICS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service
Instruments / Analyzers
Assay Kits, Reagents, and Consumables
Software and Connectivity Services
By Technology
Polymerase Chain Reaction (PCR-based)
Isothermal Amplification
Hybridization and Microarray Technologies
Other Technologies
By Application
Infectious Diseases
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Associated Infections
Hepatitis and HIV
Oncology and Cancer Diagnostics
Hematology and Genetic Testing
By Test Location
Hospitals and Emergency Rooms
Physician Offices, Clinics, and Urgent Care Centers
Over-the-Counter (OTC) / Self-Testing and Homecare Settings
Research and Academic Laboratories
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America POC Molecular Diagnostics Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
7.5. North America POC Molecular Diagnostics Market Size Outlook by Type
7.6. North America POC Molecular Diagnostics Market Size Outlook by Application
7.7. North America POC Molecular Diagnostics Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US POC Molecular Diagnostics Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada POC Molecular Diagnostics Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico POC Molecular Diagnostics Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico POC Molecular Diagnostics Companies
CHAPTER 8- EUROPE POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe POC Molecular Diagnostics Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
8.5. Europe POC Molecular Diagnostics Market Size Outlook by Type
8.6. Europe POC Molecular Diagnostics Market Size Outlook by Application
8.7. Europe POC Molecular Diagnostics Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany POC Molecular Diagnostics Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France POC Molecular Diagnostics Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK POC Molecular Diagnostics Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain POC Molecular Diagnostics Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy POC Molecular Diagnostics Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe POC Molecular Diagnostics Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe POC Molecular Diagnostics Companies
CHAPTER 9- ASIA PACIFIC POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific POC Molecular Diagnostics Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Type
9.6. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Application
9.7. Asia Pacific POC Molecular Diagnostics Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China POC Molecular Diagnostics Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan POC Molecular Diagnostics Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India POC Molecular Diagnostics Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea POC Molecular Diagnostics Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia POC Molecular Diagnostics Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia POC Molecular Diagnostics Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America POC Molecular Diagnostics Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
10.5. South and Central America POC Molecular Diagnostics Market Size Outlook by Type
10.6. South and Central America POC Molecular Diagnostics Market Size Outlook by Application
10.7. South and Central America POC Molecular Diagnostics Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil POC Molecular Diagnostics Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina POC Molecular Diagnostics Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America POC Molecular Diagnostics Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America POC Molecular Diagnostics Companies
CHAPTER 11- MIDDLE EAST AND AFRICA POC MOLECULAR DIAGNOSTICS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa POC Molecular Diagnostics Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa POC Molecular Diagnostics Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Type
11.6. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Application
11.7. Middle East and Africa POC Molecular Diagnostics Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia POC Molecular Diagnostics Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE POC Molecular Diagnostics Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa POC Molecular Diagnostics Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa POC Molecular Diagnostics Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in POC Molecular Diagnostics Industry
Abbott Laboratories
Cepheid (Danaher Corporation)
Roche Diagnostics
bioM?rieux SA
QuidelOrtho Corporation
Hologic, Inc.
Thermo Fisher Scientific
QIAGEN N.V.
Becton, Dickinson and Company
Meridian Bioscience
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
